A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer.

"IO Biotech enrols all subjects in Phase II trial of cancer combination therapy" was originally created and published by ...

(OTCQB: BIXT) (the "Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Cancer is a multifactorial disease that affects millions of individuals worldwide and has a profound impact on public health. The heterogeneity of solid ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...

Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...

A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...